α-Linolenic Acid-Valproic Acid Conjugates: Toward Single-Molecule Polypharmacology for Multiple Sclerosis.
Journal
ACS medicinal chemistry letters
ISSN: 1948-5875
Titre abrégé: ACS Med Chem Lett
Pays: United States
ID NLM: 101521073
Informations de publication
Date de publication:
10 Dec 2020
10 Dec 2020
Historique:
received:
07
07
2020
accepted:
23
10
2020
entrez:
17
12
2020
pubmed:
18
12
2020
medline:
18
12
2020
Statut:
epublish
Résumé
Multiple sclerosis (MS) is a complex inflammatory, degenerative, and demyelinating disease of the central nervous system. Although treatments exist, MS cannot be cured by available drugs, which primarily target neuroinflammation. Thus, it is feasible that a well concerted polypharmacological approach able to act at multiple points within the intricate network of inflammation, neurodegeneration, and demyelination/remyelination pathways would succeed where other drugs have failed. Starting from reported beneficial effects of α-linolenic acid (ALA) and valproic acid (VPA) in MS, and by applying a rational strategy, we developed a small set of codrugs obtained by conjugating VPA and ALA through proper linkers. A cellular profiling identified
Identifiants
pubmed: 33329762
doi: 10.1021/acsmedchemlett.0c00375
pmc: PMC7734798
doi:
Types de publication
Journal Article
Langues
eng
Pagination
2406-2413Informations de copyright
© 2020 American Chemical Society.
Déclaration de conflit d'intérêts
The authors declare no competing financial interest.
Références
Sci Rep. 2019 Jan 29;9(1):822
pubmed: 30696832
Drug Des Devel Ther. 2019 Oct 18;13:3591-3605
pubmed: 31695329
J Neuromuscul Dis. 2019;6(1):43-54
pubmed: 30452422
CNS Drugs. 2013 Oct;27(10):799-815
pubmed: 23955320
J Neurol. 2012 Jun;259(6):1199-205
pubmed: 22160466
Curr Mol Pharmacol. 2009 Jan;2(1):95-109
pubmed: 20021450
Mult Scler. 2019 Oct;25(12):1633-1640
pubmed: 30230957
Neurochem Res. 2014 Sep;39(9):1621-33
pubmed: 24482021
J Biol Chem. 2012 Aug 17;287(34):28656-65
pubmed: 22733814
Front Pharmacol. 2019 Mar 22;10:286
pubmed: 30967783
Nat Rev Neurosci. 2017 Nov 16;18(12):753-769
pubmed: 29142295
Semin Immunopathol. 2015 Nov;37(6):591-605
pubmed: 26251238
Eur J Immunol. 2007 May;37(5):1290-301
pubmed: 17407101
J Med Chem. 2008 Feb 14;51(3):347-72
pubmed: 18181565
Sci Rep. 2018 Nov 7;8(1):16457
pubmed: 30405207
Acta Neuropathol. 2010 Jan;119(1):37-53
pubmed: 19847447
Mult Scler Relat Disord. 2012 Jan;1(1):15-28
pubmed: 25876447
Nat Rev Dis Primers. 2018 Nov 8;4(1):43
pubmed: 30410033
J Med Chem. 2016 Feb 11;59(3):1217-31
pubmed: 26784936
Lancet Neurol. 2010 Mar;9(3):299-308
pubmed: 20170843
ACS Pharmacol Transl Sci. 2019 Nov 14;2(6):372-386
pubmed: 32259071
Mult Scler. 2019 Jun;25(7):987-993
pubmed: 29862891
Med Res Rev. 2020 Jun 19;:
pubmed: 32557696
J Med Chem. 2017 Jan 12;60(1):458-473
pubmed: 27976892
ACS Med Chem Lett. 2019 Feb 15;10(3):273-275
pubmed: 30891125
Pharmacoepidemiol Drug Saf. 2015 Mar;24(3):262-8
pubmed: 25111895
Brain. 2017 Mar 1;140(3):527-546
pubmed: 27794524
Neurodegener Dis. 2014;13(1):45-52
pubmed: 23949302
Am J Transl Res. 2011 Feb;3(2):166-79
pubmed: 21416059
Nat Clin Pract Neurol. 2009 Feb;5(2):82-92
pubmed: 19194388
Eur J Pharm Sci. 2010 Dec 23;41(5):571-88
pubmed: 20888411
Brain Res. 1991 Mar 29;544(2):345-8
pubmed: 2039949
Prog Brain Res. 2019;245:119-144
pubmed: 30961866